MedPath

Monomethyl fumarate

Generic Name
Monomethyl fumarate
Brand Names
Bafiertam
Drug Type
Small Molecule
Chemical Formula
C5H6O4
CAS Number
2756-87-8
Unique Ingredient Identifier
45IUB1PX8R
Associated Conditions
-
Associated Therapies
-
biospace.com
·

10 Promising IgA Nephropathy Drugs in Line to Get Approval

IgA nephropathy affects 25-50 per million annually, with 20–40% progressing to end-stage kidney disease. Diagnosed cases in the US are expected to reach 135,000 by 2030. Treatments include ACE inhibitors , ARBs , corticosteroids , and immunosuppressants . FDA-approved treatments are TARPEYO, FILSPARI , and FABHALTA . The IgA nephropathy market is projected to reach ~USD 4.1 billion by 2034, driven by novel therapies like Novartis Atrasentan , Otsuka/ Visterra ’s Sibeprenlimab , Vertex/Alpine’s Povetacicept , and others.
springermedizin.de
·

Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Anticoagulants, sildenafil , and ERAs are conditionally against use in IPF. Antacid s are conditionally recommended for GERD symptoms. Sildenafil may be considered for severe pulmonary hypertension. Prednisolone trial for cough is appropriate. Thalidomide may benefit chronic cough. Nintedanib and pirfenidone are recommended for IPF, with considerations for FVC decline. NAC is not recommended for routine IPF treatment. Corticosteroid s are not recommended for chronic IPF, except for cough relief.
biospace.com
·

Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis

Aurinia Pharmaceuticals announces Japanese approval of voclosporin , in combination with mycophenolate mofetil , for treating lupus nephritis, based on the AURORA Clinical Program data.
pmc.ncbi.nlm.nih.gov
·

Current and future advances in practice: IgG4-related disease

IgG4-RD is a fibroinflammatory disease affecting multiple organs, with B and T cells playing key roles in its pathogenesis. Diagnosis requires clinicopathological correlation due to the lack of specific tests. Glucocorticoids are effective but limited by toxicity, prompting research into glucocorticoid-sparing agents. B cell-targeted therapies like rituximab show promise, though more randomized trials are needed. Untreated IgG4-RD can lead to irreversible organ damage, emphasizing the need for close monitoring and long-term immunosuppression in some cases.
© Copyright 2025. All Rights Reserved by MedPath